NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Helen TorleyCEO;Pres2026-09-114,508$107.55
$484.83kSell
Helen TorleyCEO;Pres2026-09-1115,492$107.15
$1.66MSell
Helen TorleyCEO;Pres2026-09-1120,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-09-1014,588$107.01
$1.56MSell
Helen TorleyCEO;Pres2026-09-105,412$107.58
$582.23kSell
Helen TorleyCEO;Pres2026-09-1020,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-09-09100$108.67
$10.87kSell
Helen TorleyCEO;Pres2026-09-0920,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-09-0913,304$107.22
$1.43MSell
Helen TorleyCEO;Pres2026-09-096,596$107.82
$711.19kSell

1 of 16

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk23.47%26,633,924$2.83BInsider
Gregory Ian Frost3.21%3,641,380$386.90MInsider
Helen Torley0.68%767,780$81.58MInsider
Jonathan E. Lim0.63%710,000$75.44MInsider
John Stuart Patton0.36%412,706$43.85MInsider
Kathryn E. Falberg0.32%358,253$38.06MInsider
Robert Engler0.24%273,176$29.02MInsider
Connie Matsui0.16%183,035$19.45MInsider
Kenneth J. Kelley0.16%179,833$19.11MInsider
Michael J. Labarre0.15%173,756$18.46MInsider

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO0.11%30.26%Net SellingNet Selling
MDGL0.04%99.96%Net SellingNet Selling
CORT0.04%99.96%Net BuyingNet Selling
BMRN0.10%1.81%Net SellingNet Selling
TECH0.11%2.53%Net SellingNet Selling

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 0.11% institutional shareholders, 30.26% Halozyme Therapeutics insiders, and 69.63% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 23.47% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $2.89B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.